A YALE SPINOUT / NEUROLOGICAL BIOMARKER RESEARCH

AstroScope™
A blood-based platform
for neurological disease.

AstroScope combines dozens of RNA biomarkers from astrocyte-enriched blood vesicles into signatures of neurological disease, progression, and drug response.

For biopharma teams, the platform brings a molecular view of neurological disease into biomarker and clinical-trial research. Secondary progressive MS is our lead program, validated for research use, with development toward clinical use continuing.

Research use only. Not for clinical diagnostic use.

Illustrative cutaway of an exosome showing its membrane and molecular cargo, from East Rock’s company artwork.
CNS-specific biology. A blood-based approach.Illustrative exosome cutaway · East Rock scientific artwork
EAST ROCK DIAGNOSTICS INC.Discover the platform NEW HAVEN, CONNECTICUT

01 / THE PROBLEM IN NEUROLOGY

Measuring disease biology in living patients

Neurological disease
needs more informative
molecular readouts.

Symptoms and imaging reveal important aspects of neurological disease. Drug developers also need accessible ways to investigate the molecular biology driving progression and differences in treatment response.

Blood contains vesicles from many tissues. AstroScope enriches a cell-associated fraction to investigate CNS-related signals within that mixture. Our first application addresses the challenge of recognizing MS progression.

The platform is designed to support disease-specific signatures on a shared sample-processing and analysis foundation—allowing research across neurological conditions.

The research need behind the Colton project ↗
01

Identify progression

Investigate objective molecular differences between progressive and clinically stable MS.

02

Predict disability

Study whether a blood sample contains signals associated with later clinical progression.

03

Show Mechanisms

Explore how disease biology and treatment exposure relate to RNA signatures over time.

02 / THE ASTROSCOPE PLATFORM

CNS-focused enrichment → dozens of biomarkers → disease-specific signatures

AstroScope.
Dozens of biomarkers.
One combined signature.

A rowing crew moving together in one boat, illustrating multiple biomarkers contributing to one combined signature.

AstroScope combines dozens of RNA biomarkers from astrocyte-associated vesicles in blood. AI identifies patterns linked to CNS disease, progression, and treatment response.

MS is validated for research use; clinical development continues.

Read the Yale technology overview ↗
Scientific illustration showing an astrocyte releasing exosomes toward a recipient cell.
Astrocyte and exosome illustration from East Rock’s scientific materials. Not to scale.

WHAT IS AN EXOSOME?

Small vesicles carrying
dozens of instructions.

Exosomes are small extracellular vesicles released by cells. They carry molecules, including RNA and proteins, that can reflect the state of the cells that released them.

Why astrocytes?

Astrocytes support neurons, connect with blood vessels, and play key roles in disease and repair. A single human astrocyte can span up to two million synapses.

Why dozens of biomarkers combined into a signature?

Biomarkers working in unison can reveal patterns that individual markers miss. By focusing on astrocyte-associated signals, AstroScope narrows the analysis to questions relevant to CNS disease.

Read our team’s review of CNS exosome biomarkers ↗

HOW ASTROSCOPE WORKS

From a blood sample
to a biomarker signature.

The workflow combines sample processing, vesicle enrichment, RNA profiling, and study-specific analysis. It is currently a research tool.

01

Blood draw

Collect a blood sample and prepare plasma or serum.

INPUT / PLASMA OR SERUM
02

Enrich the vesicles

AstroScope isolates astrocyte-marker–labeled exosomes from plasma or serum.

OUTPUT / ENRICHED EV FRACTION
03

Profile the RNA

Extract and measure vesicle RNA cargo. Dozens of disease-specific, cell-specific markers are isolated.

OUTPUT / RNA PROFILE
04

Discover signatures with AI

Use AI modeling, including machine learning, to discover patterns across dozens of RNA biomarkers.

OUTPUT / COMBINED BIOMARKER SIGNATURE
05

Identify new signatures

Identify diagnostic, predictive, prognostic, and drug-response signatures, including signals of disease change and progression rate.

OUTPUT / SIGNATURES FOR DEFINED RESEARCH QUESTIONS

Enrichment does not imply absolute cell specificity. Methods and deliverables are study-specific. AstroScope is not currently offered for clinical diagnosis.

See the assay workflow from our company presentation +
Company diagram: plasma sample, astrocyte-enriched exosomes, content profiling, and computational analysis for candidate biomarkers.
Original workflow artwork from East Rock External 1, slide 7. Describes the research platform and its development objectives.

ONE PLATFORM / MULTIPLE PROGRAMS

A platform for
biomarker discovery.

AstroScope is a platform for discovering biomarkers and signatures across many diseases.

As new questions arise, comparisons between patient groups, disease states, and treatment responses can uncover new signals.

How the platform supports partnerships →
AstroScope program map showing an exosome connected to MS, ALS, long COVID, aging, NMO, PD, SLE, and additional programs.

DEVELOPMENT PIPELINE

From Discovery
to Clinic

Each program advances through discovery, research validation, and study-specific development. Clinical products require additional evidence and the applicable regulatory pathway.

ProgramDiscoveryResearch validationTrial integrationClinical product
Progressive MSLEAD PROGRAMSignature identifiedValidated for RUOIn developmentClinical work continues
ALSSignature identifiedResearch underwayIn developmentNot established
Brain agingSignature identifiedEarly researchNot establishedNot established
Long COVIDSignature identifiedEarly researchNot establishedNot established
NMOSD / NMOExploratoryNot establishedNot establishedNot established
RemyelinationExploratoryNot establishedNot establishedNot established

MS is validated for research use. Validation continues for the other discovery programs. Clinical products require additional evidence and regulatory review.

03 / SPMS PROGRAM & REPORTED DATA

MS validated for RUO / Clinical development continues

Diagnosing progression.
Predicting future progression.

Our lead program focuses on secondary progressive multiple sclerosis (SPMS) and is validated for research use. Work toward clinical use continues.

We are investigating blood-based molecular signatures that may help researchers identify MS progression and study signals that precede clinical recognition.

Discuss the SPMS program

MS / RESEARCH-USE VALIDATION

Two research questions.
Two reported results.

Company-reported results · Publication pending
0.95AUC

Identifying MS progression

0.97AUC

Predicting MS progression two years before a physician

Company-described studies use blinded retrospective analyses of previously collected samples from prospective Phase III randomized controlled trials.

Research use only

AUC measures how well a model separates groups; it is not percentage accuracy. These are company-reported research findings, with publications pending. They do not establish prospective clinical utility.

Study context and evidence
0.95 AUCCompany PCA plot showing progressive MS samples in red and stable MS samples in blue.
Progressive versus stable MSCompany research: principal-component visualization of molecular profiles in progressive and stable MS.
0.97 AUCCompany bar chart of normalized progression-associated microRNA expression in controls, stable MS, and intervals before MS progression.
Predicting future progressionCompany research: microRNA expression across intervals preceding HCP clinical measures of progression. Publication pending.

STUDY CONTEXT

Blinded retrospective analyses of Phase III trial samples linked AstroScope exosomal microRNA signatures to MS progression, including progression 18–24 months after blood collection.

Source: East Rock Diagnostics research presentations · Research use only · SPMS publications pending.

WHY IT MATTERS

Mobility. Independence.
Everyday life.

For people living with MS, changes in walking, balance, and fatigue can affect daily routines and independence. These are the everyday stakes behind the search for better ways to understand progression.

East Rock’s goal is to give researchers—and, with further clinical validation, care teams—the tools for better clinical decisions by patients and physicians.

Illustrative scene of two friends walking in a park, one using a cane.
Illustrative image

WHY THE DECISION GAP MATTERS

Relapses and progression
are different measurements.

Disability can accumulate after relapses and independently of relapse activity. A quieter relapse history does not, by itself, answer whether underlying disability is progressing.

AstroScope’s lead research program asks whether a molecular signature can help distinguish progressive from stable MS and flag later progression.

Read the clinical evidence on relapse-independent progression ↗
RELAPSE-ASSOCIATED WORSENING

Disability linked to an attack

Clinical worsening occurs in relation to a relapse.

PROGRESSION INDEPENDENT OF RELAPSE ACTIVITY

Worsening without a preceding relapse

Longitudinal measurements are needed to recognize and confirm progression.

The research question: can AstroScope inform patients, HCPs and insurers on proper treatment for progression?

INTENDED CLINICAL USES IN MS

Informing treatment decisions.

STABLE PATIENTS

Stop overtreatment.

Nearly one-third of secondary progressive MS patients are stable. Support decisions to stop unnecessary treatment in patients with stable MS.

PROGRESSIVE PATIENTS

Start treatment.

About two-thirds of secondary progressive MS patients will progress. Identify the patient subpopulation most likely to benefit from treatment aimed at preventing progression.

TREATMENT RESPONSE

Switch or stop treatment.

Monitor responses to help assess whether treatment should continue, change, or stop.

AstroScope is currently for research use only. These clinical applications require further validation.

04 / BUSINESS MODEL & MARKET

Available now: RUO analysis and research collaborations

Research partnerships.
A route to
diagnostic products.

East Rock offers paid research-use sample analysis and collaborative biomarker studies for biopharma teams developing neurological therapies.

BUSINESS MODEL / FEEDBACK LOOP

01 / PHARMA SERVICES

Research revenue
& trial data

Sponsored research and trial partnerships generate revenue with existing signatures

Available now
Research services & collaborations

02 / MS CLINICAL DEVELOPMENT

AstroScope-MS:
clinical lead

Validate and launch a clinical test

Planned path
Clinical product development

03 / INDICATION EXPANSION

Select the next
applications

Identify new signatures

Selection criteria
Evidence, need & market size

NEW PROGRAMS → NEW PHARMA PARTNERSHIPSMore revenue and trial data support the next cycle.

ONE SHARED PLATFORM

Exosome enrichment → RNA profiling → Analysis

TRIAL DESIGN

Patient selection.

Stratify patients, balance treatment arms, and identify potential responder subpopulations.

EARLY BIOLOGICAL RESPONSE

Early decision marker
& target engagement.

Use early molecular changes to inform trial decisions and investigate target engagement and mechanism of action.

TRIAL OUTCOMES

Outcome marker.

Track treatment response and progression using molecular signatures as study-specific research outcomes.

MARKET OPPORTUNITY

A platform market.
MS as the first application.

AstroScope connects biomarker research for neurological drug development with future disease-specific diagnostic testing.

01 / GLOBAL OUTLOOKUpdated outlook

Neurological biomarkers.

Global market by application, 2023–2033.

$27.3B2033 forecast
13.1%CAGR · 2026–2033
Neurological biomarkers market by application, 2023–2033Five stacked categories, bottom to top: Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, others, and autism spectrum disorder. The vertical axis is market size in US dollar billions, from 0 to 30 with ticks every 6 billion. Eleven annual bars reproduce the updated supplied chart. Exact printed totals are 10.2 billion for 2025, 11.5 billion for 2026, and 27.3 billion for 2033. Other bar heights are approximately digitized against the source axis, and category proportions remain approximate.Market size (USD billions)0.06.012.018.024.030.020232024202510.2B202611.5B202720282029203020312032203327.3BAlzheimer’s diseaseParkinson’s diseaseMultiple sclerosisOthersAutism spectrum disorder
Grand View Research, 2026–2033 report ↗ · Printed totals of $10.2B (2025), $11.5B (2026), and $27.3B (2033) are preserved. Other bar heights and segment proportions are approximated from the supplied chart’s scale. View updated original ↗
02 / BIOMARKER CUSTOMERS2024 · Approximate shares

Clinical diagnostics:
one of three customer segments.

Pharma and biotech account for about half of the supplied 2024 market view.

Rounded proportions from the supplied graphic; exact segment shares remain unconfirmed.

2024 neurological biomarkers customer mix — approximateApproximate proportions visually read from the supplied unlabeled pie chart: pharma and biotech companies about one half, clinical diagnostics about one third, research organizations about one sixth. These are not independently verified exact shares.2024END-USE MIX
Pharma & biotech
companies
≈1/2
Clinical
diagnostics
≈1/3
Research
organizations
≈1/6
Source: supplied 2024 graphic attributed to Grand View Research. View original ↗
About these approximate shares

The original pie has no numeric share labels. The displayed 1/2 / 1/3 / 1/6 split is a rounded visual estimate, not an exact publisher data table. Grand View Research’s indexed pharma/biotech figure of $4,565.8M supports a share of about half of the $9.1B total; other publisher pages give conflicting end-use descriptions. Exact shares require reconciliation before an unqualified presentation.

Publisher’s pharma/biotech data ↗ · 2025 press release ↗
03 / BIOPHARMA CUSTOMER CONTEXTHistorical forecast

The MS therapeutic market is growing.

Global market by drug type, from the supplied 2022–2032 forecast.

$41B2032 forecast
3.8%Reported CAGR
Global multiple sclerosis drugs market by type — historical forecastFour stacked categories, from bottom to top: immunomodulators, interferons, immunosuppressants, and other types. Segment proportions are approximately traced from the original image; exact category data are not supplied. Annual totals transcribed from the supplied Market.us 2022–2032 chart, in billions of US dollars: 2022: 28.2, 2023: 29.3, 2024: 30.2, 2025: 31.7, 2026: 33.1, 2027: 34.1, 2028: 34.9, 2029: 36.3, 2030: 37.5, 2031: 38.9, 2032: 41. The original chart reports 3.8 percent CAGR. This is the supplied historical forecast, not a current forecast.01020304028.2202229.3202330.2202431.7202533.1202634.1202734.9202836.3202937.5203038.92031412032USD billionsSupplied 2022–2032 forecastImmunomodulatorsInterferonsImmunosuppressantsOther types
Source: Market.us · Supplied 2022–2032 forecast (November 2023). Totals reproduced as labeled; stacked proportions traced approximately from the source image. View original ↗

Drug-market context for biopharma partnerships; excluded from East Rock’s diagnostic opportunity. This historical forecast is not presented as a current market estimate.

View annual values
Global MS drugs market, supplied forecast (USD billions)
YearMarket size
202228.2
202329.3
202430.2
202531.7
202633.1
202734.1
202834.9
202936.3
203037.5
203138.9
203241
04 / EAST ROCK COMPANY MODELInitial US opportunity

AstroScope is the first fluid diagnostic for disease progression.

The company’s initial model starts with US patients over age 45 and assumes full use of one to two assays per year.

1 millionUS MS patients
in the company model

680,000 over age 45
68% of the modeled population

680,000modeled patients
1–2assays per year
$2,500assumed price / assay

MODELED ANNUAL US OPPORTUNITY

$1.7–3.4B
Exact calculation$1.7B–$3.4B / year
Illustrative global scenario 4× the US model

The original slide assumes a fourfold global multiplier. Applied to the unrounded US calculation, it gives $6.8–13.6B per year. This is a company scenario, not an independently sized global market. Country-specific eligibility, access, use, and pricing are not modeled.

Source: East Rock company presentation, slide 10; assay-price assumption updated to $2,500 by the company, October 2026. Population, testing frequency, price, and global multiplier are company assumptions. Final AstroScope pricing has not been set; clinical availability, adoption, reimbursement, and eligibility determine realized revenue. View original ↗

Broader US MS model & adoption projections$6B / year

The separate broader company model uses 1.2 million US patients × two assays per year × $2,500 per assay, giving $6 billion annually at full modeled utilization.

$60MAnnual revenue at 1% adoption
$240MAnnual revenue at 4% adoption

These are company projections, not current revenue. Clinical availability and access are assumed.

AstroScope can solve
critical trial questions.

Discuss available samples, clinical annotations, the analysis plan, and research deliverables with our team.

Discuss a research collaboration ↗

Endpoint roles, analysis plans, and interpretation are defined for each study and its intended research use. Clinical diagnostic products remain in development.

05 / SCIENTIFIC FOUNDATION

Grounded in research. Built for what comes next.

Research, recognition,
and publications.

AstroScope grew from research at Yale. Public recognition of the underlying work provides a foundation for the next stage of investigation.

Awards above recognize the investigators and research projects at Yale. They do not imply institutional endorsement of East Rock Diagnostics.

06 / COMPANY & PEOPLE

Neuroscience, assay development, and biopharma partnerships

The team building
AstroScope.

East Rock Diagnostics Inc. is a Yale spinout and pre-seed diagnostics company translating extracellular vesicle research into tools for neurological biomarker studies.

Our team combines MS clinical expertise, vesicle and RNA assay development, and research partnerships across biopharma and academia. We have access to world-class clinical data and patient biosamples from Yale Neurology and the MS clinic, as well as the MS Brain Bank.

Ilir Topalli, PhD

COMPANY STRATEGY & PARTNERSHIPS

Ilir Topalli, PhD

Chief Executive Officer & Co-founder

Ilir Topalli leads East Rock Diagnostics’ company strategy and biopharma partnerships. He brings experience across neuroscience, medical affairs, and academic–industry research collaboration, with a longstanding focus on multiple sclerosis. He previously served as President of Alison Pharmaceuticals Inc. Ilir is a biotech analyst and investment advisor for e*Healthline.

Read full biography

At Bristol Myers Squibb, he served as Global Academic Research Collaborations Lead within Worldwide Strategic Collaborations. Previously, he was National Scientific Director, Scientific Partnerships at Biogen, where he led the US investigator-initiated research program across the neurology portfolio. At MedDay Pharmaceuticals, he directed global medical sciences and evidence-generation activities supporting a Phase III progressive MS program.

Ilir holds a PhD in Neuroscience from Albert Einstein College of Medicine. At East Rock, he connects the platform’s scientific development with the needs of research partners and the company’s path to commercialization.

Alison Pharmaceuticals Inc. · Bristol Myers Squibb · Biogen · MedDay Pharmaceuticals · e*Healthline
David Pitt, MD

CLINICAL & TRANSLATIONAL SCIENCE

David Pitt, MD

Co-founder

David Pitt is a clinician-scientist and Associate Professor of Neurology at Yale whose work connects MS pathology with the development of blood-based biomarkers. He provides care at the Yale Multiple Sclerosis Clinic and serves as Co-Director of the National Multiple Sclerosis Brain Bank.

Read full biography

His laboratory investigates how cell-specific extracellular vesicles can reveal molecular processes in the central nervous system. This research underpins AstroScope and East Rock’s focus on detecting and understanding MS progression.

David trained in medicine in Germany, completed postdoctoral training and a neurology residency at Albert Einstein College of Medicine, and undertook a neuroimmunology fellowship at Washington University in St. Louis before joining Yale. His AstroScope-related work has received support through Yale’s Colton Center and Blavatnik Fund.

Pitt Lab website ↗
Jonathan S. Weerakkody, PhD

EXTRACELLULAR VESICLES & RNA PROFILING

Jonathan S. Weerakkody, PhD

Co-founder

Jonathan Weerakkody develops extracellular vesicle enrichment, RNA profiling, and computational approaches for blood-based measurement of neurological disease. At East Rock, he helps translate this work into AstroScope’s research-use platform.

Read full biography

His research at Yale focuses on astrocyte-associated vesicles and RNA signatures linked to MS progression. He previously helped develop a photocleavable lipid nanoprobe platform for high-purity, size-specific vesicle isolation, building on doctoral work in biophysics and biomimetic biosensors.

Jonathan’s work has appeared in journals including Advanced Functional Materials and Biosensors and Bioelectronics. His MS biomarker research is supported by the Patterson Trust Mentored Research Award and Yale’s Colton Center for Autoimmunity.

Yale researcher profile ↗

OUR PEOPLE

Yale Ventures associates

OUR PEOPLE

Summer 2026 interns

Shamiek Cooper

Shamiek Cooper

Summer Internship Program Director · 2026

LinkedIn
Emma Appiah

Emma Appiah

Summer intern

Executive Operations & Social Media

LinkedIn

Stella Zheng

Summer intern

Social Media

Imani Bilicic-Houmita

Summer intern

Executive Operations

LinkedIn

07 / PRESENTATIONS & EXPLAINERS

The platform and the people behind it

AstroScope explained.
Meet the founders.

Explore AstroScope through the company overview and founder presentations.

These videos are linked from East Rock’s existing website and the Pitt Lab project. They are presented in their original context.

ASTROSCOPE OVERVIEW

Exosomes and the AstroScope platform

An animated explanation of exosomes, their molecular cargo, and AstroScope’s focus on astrocyte-associated signals in blood.

Watch on YouTube

YALE INNOVATION SUMMIT / 2025

The clinical need and business model

Ilir Topalli discusses the MS decision gap, AstroScope’s data, and the research-partnership business model. His presentation begins about 2:15 into the recording.

Watch on YouTube

YALE LIFE SCIENCE PITCHFEST / 2025

From discovery to translation

David Pitt presents AstroScope at Yale’s 2025 Life Science PitchFest.

Watch on Vimeo

Pressing play connects to YouTube or Vimeo. These historical presentations may describe earlier research and development plans. AstroScope’s current research-use status is described above.

LET’S START A CONVERSATION

Discuss AstroScope
with our team.

For research collaborations, biopharma partnerships, and investor conversations, connect with East Rock Diagnostics.

Get in touch
info@eastrockdx.com

New Haven, Connecticut

Email opens in your mail app.
Please do not send personal health information.